Skip to content
Cellectis logo — 
Cellectis is developing genetic medicines for diseases that...

Cellectis

Cellectis is developing genetic medicines for diseases that today demand a lifetime of treatment.

Founded 1999 France France 242 employees IPO Total: $598.05M Biotechnology, Pharmaceutical

General Information

Company Name Cellectis
Founded Year 1999
Location France France
Employees 242
Industries Biotechnology, Pharmaceutical
Funding Stage IPO
Business Model B2B, Platform, B2B2B
Revenue Model Licensing, Product Sales, Performance Based
Offices as of Nov 2026
Paris, France New York, United States Raleigh, United States
Social

BounceWatch is an independent company data service, not affiliated with Cellectis. To contact Cellectis, visit cellectis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Cellectis compare?

A PDF of Cellectis and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Cellectis soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Oct 27, 2026

Cellectis presented preclinical data on .HEAL-101 at the European Society of Gene and Cell Therapy.

About Cellectis

Cellectis is a global clinical-stage biopharmaceutical company focused on developing pioneering treatments to address unmet medical needs. Established in 1999, the company has leveraged its 26 years of expertise in genome editing, especially in the fields of immuno-oncology and gene therapy. Its mission is underscored by the slogan, "Cellectis is developing life-changing product candidates to target and eradicate cancer cells."

Notably, Cellectis has developed allogeneic CAR-T cells using proprietary gene-editing technology. Its primary clinical programs are targeting B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL). With full vertical integration from Paris for production of starting materials to Raleigh, NC for manufacturing finished products, Cellectis ensures uncompromised quality across its operations.

Strategic collaborations with industry leaders like AstraZeneca and Allogene Therapeutics further bolster its research in oncology and rare diseases. Headquartered in Paris, with additional offices in New York and Raleigh, the company is publicly traded on both the Nasdaq Global Market and Euronext Growth under the tickers CLLS and ALCLS, respectively.

Business keywords: biopharmaceutical, clinical-stage, genome editing, immuno-oncology, gene therapy, CAR-T cell therapy, allogeneic therapies, B-cell acute lymphoblastic leukemia, non-Hodgkin lymphoma, vertical integration, collaborations, oncology, immunology, rare diseases, manufacturing process

Services & Products

Gene-edited therapeutics development
Clinical-stage biotechnology research
Innovative gene and cell therapies

Target Customers

Cancer patients Healthcare providers Pharmaceutical partners Biotechnology companies

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $140.00M 1
AstraZeneca
01 May 2024
Post-IPO Equity €15.00M 1
European Investment Bank
01 Jan 2024
Post-IPO Equity $20.20M -
01 Feb 2023
Post IPO Convertible $20.00M -
01 Apr 2022
Post-IPO Equity €132.00M -
01 Apr 2018
Post-IPO Equity $228.25M -
01 Mar 2015
IPO €25.20M -
01 Feb 2007
Series C €5.60M 4
Andera Partner, BankInvest Group +2
01 Jun 2005
Series B €8.00M 4
Andera Partner, BankInvest Group +2
01 May 2002
Series A €3.80M -
01 Nov 2000

View All 11 Funding Rounds

Cellectis Alternatives & Competitors

Cellectis vs
Mustang Bio
Mustang Bio United States

A fortress biotech Company

IPO
43 employees
Biotechnology, Pharmaceutical
Cellectis vs

Pioneering DARPin Therapeutics for Patients

Post-IPO Equity
174 employees
Biotechnology, Pharmaceutical
Cellectis vs
Vor Bio
Vor Bio United States

Vor Bio's vision is to cure blood cancers through cell and genome engineering.

Post-IPO Equity
110 employees
Biotechnology, Health Care

FAQ About Cellectis

Cellectis is developing genetic medicines for diseases that today demand a lifetime of treatment.
Cellectis was founded in 1999.
Cellectis is headquartered in France. As of Nov 2026, it also has offices in Paris, France, New York, United States and Raleigh, United States.
Cellectis operates in Biotechnology and Pharmaceutical. Its work centres on biopharmaceutical, clinical-stage, genome editing and immuno-oncology. Its customers include Cancer patients, Healthcare providers and Pharmaceutical partners.
Cellectis has a B2B, Platform and B2B2B business model. Its revenue comes from Licensing, Product Sales and Performance Based.
Cellectis has approximately 242 employees.
Cellectis has completed 11 funding rounds, raising a total of $598.05M. The latest funding stage is IPO.
Cellectis offers: Gene-edited therapeutics development, Clinical-stage biotechnology research, Innovative gene and cell therapies.
Top alternatives and competitors to Cellectis include Mustang Bio, Molecular Partners, Vor Bio, Arcellx, Kincell Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cellectis and Mustang Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Cellectis, https://bouncewatch.com/company/cellectis-1, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout